Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
or

Perspective Therapeutics Inc (CATX)

Perspective Therapeutics Inc (CATX)
2.19 x 20 2.45 x 1
Post-market by (Cboe BZX)
2.39 -0.04 (-1.65%) 04/25/25 [NYSE Arca]
2.19 x 20 2.45 x 1
Post-market 2.39 unch (unch) 16:01 ET
Quote Overview for Fri, Apr 25th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
2.33
Day High
2.45
Open 2.42
Previous Close 2.43 2.43
Volume 557,900 557,900
Avg Vol 1,003,580 1,003,580
Stochastic %K 93.96% 93.96%
Weighted Alpha -72.66 -72.66
5-Day Change +0.45 (+23.20%) +0.45 (+23.20%)
52-Week Range 1.60 - 19.05 1.60 - 19.05
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 133,292
  • Shares Outstanding, K 74,051
  • Annual Sales, $ 1,450 K
  • Annual Income, $ -79,280 K
  • EBIT $ -67 M
  • EBITDA $ -41 M
  • 60-Month Beta 1.20
  • Price/Sales 121.72
  • Price/Cash Flow N/A
  • Price/Book 0.57

Options Overview Details

View History
  • Implied Volatility 170.07% ( -23.55%)
  • Historical Volatility 89.00%
  • IV Percentile 52%
  • IV Rank 19.57%
  • IV High 847.26% on 03/21/25
  • IV Low 5.25% on 08/13/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 9
  • Volume Avg (30-Day) 15
  • Put/Call OI Ratio 0.05
  • Today's Open Interest 1,218
  • Open Int (30-Day) 1,779

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.28
  • Number of Estimates 6
  • High Estimate -0.26
  • Low Estimate -0.31
  • Prior Year -0.20
  • Growth Rate Est. (year over year) -40.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.60 +49.38%
on 04/09/25
Period Open: 2.47
2.49 -4.02%
on 03/26/25
-0.08 (-3.24%)
since 03/25/25
3-Month
1.60 +49.38%
on 04/09/25
Period Open: 4.01
4.11 -41.92%
on 01/27/25
-1.62 (-40.40%)
since 01/24/25
52-Week
1.60 +49.38%
on 04/09/25
Period Open: 16.00
19.05 -87.45%
on 05/15/24
-13.61 (-85.06%)
since 04/25/24

Most Recent Stories

More News
Perspective Therapeutics Announces Acceptance of VMT-α-NET and VMT01 Data for Presentation at the 2025 ASCO Annual Meeting

CATX : 2.39 (-1.65%)
Perspective Therapeutics to Provide Business Highlights and Report First Quarter 2025 Financial Results

CATX : 2.39 (-1.65%)
Perspective Therapeutics Announces First Patient Dosed with [212Pb]VMT01 Monotherapy at 1.5 mCi in a Phase 1/2a Study of MC1R-Positive Metastatic Melanoma

CATX : 2.39 (-1.65%)
Perspective Therapeutics to Participate in Upcoming April Investor Conferences

CATX : 2.39 (-1.65%)
Perspective Therapeutics Provides Recent Business Highlights and Reports Full Year 2024 Results

CATX : 2.39 (-1.65%)
Perspective Therapeutics Announces First Patient Dosed with [212Pb]VMT01 in Combination with Nivolumab in a Phase 1/2a Study of MC1R-Positive Metastatic Melanoma

CATX : 2.39 (-1.65%)
Perspective Therapeutics to Present at Upcoming March Investor Conferences

CATX : 2.39 (-1.65%)
Perspective Therapeutics to Provide Business Highlights and Report Full Year 2024 Financial Results

CATX : 2.39 (-1.65%)
Perspective Therapeutics to Participate in Upcoming February Investor Conferences

CATX : 2.39 (-1.65%)
Perspective Therapeutics Continues to Pursue Dose Escalation of [212Pb]VMT-α-NET in its Ongoing Phase 1/2a Clinical Trial Based on Updated Interim Data Presented at the 2025 ASCO Gastrointestinal Cancers Symposium

CATX : 2.39 (-1.65%)

Business Summary

Perspective Therapeutics Inc. is a medical technology and radiopharmaceutical company which provide advanced treatment applications for cancers. The Company is the sole producer of Cesium-131 brachytherapy seeds. Perspective Therapeutics Inc., formerly known as Isoray Inc., is based in RICHLAND, Wash....

See More

Key Turning Points

3rd Resistance Point 2.57
2nd Resistance Point 2.51
1st Resistance Point 2.45
Last Price 2.39
1st Support Level 2.33
2nd Support Level 2.27
3rd Support Level 2.21

See More

52-Week High 19.05
Fibonacci 61.8% 12.38
Fibonacci 50% 10.32
Fibonacci 38.2% 8.27
Last Price 2.39
52-Week Low 1.60

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Value Investing Philosophies: Graham, Buffett, Bogle, and EMH in Perspective